Evidence map›Paper›PMID 39860394›Full record

ArticleJournal of clinical medicine2025

A Real-World Comparison of the Safety Profile for Immune Checkpoint Inhibitors in Oncology Patients.

Abdulrahman Alwhaibi, Miteb A Alenazi, Sultan Alghadeer, Wael Mansy, Reem A Alsaif, Nawaf E Abualreesh, Rakan J Alanazi, Abdullah Alroumi, Saleh A Alanazi

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Abdulrahman AlwhaibiDepartment of Clinical Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.ORCID 0000-0001-8519-3363
Miteb A AlenaziPharmacy Department, King Saud University Medical City, Riyadh 11411, Saudi Arabia.
Sultan AlghadeerDepartment of Clinical Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.ORCID 0000-0003-3306-0387
Wael MansyDepartment of Clinical Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.ORCID 0000-0002-7988-2717
Reem A AlsaifPharmacy Department, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh 11426, Saudi Arabia.
Nawaf E AbualreeshDepartment of Clinical Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
Rakan J AlanaziPharmacy Practice Department, College of Pharmacy, Alfaisal University, Riyadh 11533, Saudi Arabia.ORCID 0009-0000-1781-5191
Abdullah AlroumiCollege of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, Riyadh 11461, Saudi Arabia.
Saleh A AlanaziCollege of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, Riyadh 11461, Saudi Arabia.

Funding

King Saud University RSPD-2024R572
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

adverse effectsatezolizumabcomplicationsdurvalumabnivolumabonsetpembrolizumabside effects

Identifiers

PMID39860394
PMCPMC11765622

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.